NEW ACTIVE PHARMACEUTICAL INGREDIENTS FUNDAMENTALS EXPLAINED

“The current scenario has exposed some structural weaknesses within the EU’s medicines supply chain along with a high dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides stated. She proposed that supply chain difficulties be resolved within an EU pharmaceutical strategy expected being introduced by